Erin L Martin1, Aimee L McRae-Clark1,2,3. 1. 125 Doughty Street, 109K, Department of Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA. 2. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. 3. Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Abstract
PURPOSE OF REVIEW: Cannabis use disorder (CUD) is highly prevalent. Psychotherapy alone is not adequately effective, with few individuals achieving abstinence. Pharmacotherapeutic supplementation may improve efficacy, and the endocannabinoid system presents a target specifically dysregulated by heavy cannabis use. This review compiles current literature evaluating endocannabinoid modulation as a treatment strategy for CUD, with implications for future research. RECENT FINDINGS: Cannabinoid receptor agonists have been found to reduce cannabis withdrawal symptoms without a notable effect on relapse, and antagonists can produce severe psychiatric symptoms. Fatty acid amide hydrolase inhibitors and cannabidiol demonstrate the most promising efficacy in treating CUD thus far, but research with these compounds is still preliminary. SUMMARY: Components of the endocannabinoid system may serve as unique treatment targets with differential efficacy for the treatment of cannabis use disorder as a whole. Further research is needed exploring novel methods for targeting endocannabinoid dysfunction in CUD.
PURPOSE OF REVIEW: Cannabis use disorder (CUD) is highly prevalent. Psychotherapy alone is not adequately effective, with few individuals achieving abstinence. Pharmacotherapeutic supplementation may improve efficacy, and the endocannabinoid system presents a target specifically dysregulated by heavy cannabis use. This review compiles current literature evaluating endocannabinoid modulation as a treatment strategy for CUD, with implications for future research. RECENT FINDINGS: Cannabinoid receptor agonists have been found to reduce cannabis withdrawal symptoms without a notable effect on relapse, and antagonists can produce severe psychiatric symptoms. Fatty acid amide hydrolase inhibitors and cannabidiol demonstrate the most promising efficacy in treating CUD thus far, but research with these compounds is still preliminary. SUMMARY: Components of the endocannabinoid system may serve as unique treatment targets with differential efficacy for the treatment of cannabis use disorder as a whole. Further research is needed exploring novel methods for targeting endocannabinoid dysfunction in CUD.
Entities:
Keywords:
Cannabidiol; Cannabis Use Disorder; Dronabinol; Endocannabinoid System; FAAH; Nabiximols
Authors: Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka Journal: J Neurochem Date: 2008-07-15 Impact factor: 5.372
Authors: Annelot C M van Esbroeck; Antonius P A Janssen; Armand B Cognetta; Daisuke Ogasawara; Guy Shpak; Mark van der Kroeg; Vasudev Kantae; Marc P Baggelaar; Femke M S de Vrij; Hui Deng; Marco Allarà; Filomena Fezza; Zhanmin Lin; Tom van der Wel; Marjolein Soethoudt; Elliot D Mock; Hans den Dulk; Ilse L Baak; Bogdan I Florea; Giel Hendriks; Luciano De Petrocellis; Herman S Overkleeft; Thomas Hankemeier; Chris I De Zeeuw; Vincenzo Di Marzo; Mauro Maccarrone; Benjamin F Cravatt; Steven A Kushner; Mario van der Stelt Journal: Science Date: 2017-06-09 Impact factor: 47.728
Authors: Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley Journal: Neuropsychopharmacology Date: 2010-03-31 Impact factor: 7.853
Authors: Leah M Mayo; Anna Asratian; Johan Lindé; Lovisa Holm; Daniel Nätt; Gaëlle Augier; Niclas Stensson; Haley A Vecchiarelli; Georgia Balsevich; Robert J Aukema; Bijar Ghafouri; Primavera A Spagnolo; Francis S Lee; Matthew N Hill; Markus Heilig Journal: Mol Psychiatry Date: 2018-08-17 Impact factor: 15.992
Authors: Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran Journal: Lancet Psychiatry Date: 2020-07-28 Impact factor: 27.083
Authors: Erin C Hanlon; Esra Tasali; Rachel Leproult; Kara L Stuhr; Elizabeth Doncheck; Harriet de Wit; Cecilia J Hillard; Eve Van Cauter Journal: Sleep Date: 2016-03-01 Impact factor: 5.849
Authors: Ryan Vandrey; Maxine L Stitzer; Miriam Z Mintzer; Marilyn A Huestis; Jeannie A Murray; Dayong Lee Journal: Drug Alcohol Depend Date: 2012-08-22 Impact factor: 4.492
Authors: Morteza Abyadeh; Vivek Gupta; Joao A Paulo; Veer Gupta; Nitin Chitranshi; Angela Godinez; Danit Saks; Mafruha Hasan; Ardeshir Amirkhani; Matthew McKay; Ghasem H Salekdeh; Paul A Haynes; Stuart L Graham; Mehdi Mirzaei Journal: Biomolecules Date: 2021-09-27